Keyphrases
Obesity
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Glucose-dependent Insulinotropic Polypeptide
100%
Targeted Treatment
100%
Enteroendocrine Cells
100%
Glucagon-like
60%
Incretin Hormones
40%
Digestion
20%
Glycemic Control
20%
Blood Glucose
20%
Hyperglycemia
20%
A1 Receptor
20%
Glucose-dependent Insulinotropic Polypeptide Receptor
20%
Glucose-lowering Drugs
20%
Non-insulin
20%
Insulin Independence
20%
Agonism
20%
Effective Intervention
20%
Intestine
20%
Agonist Peptide
20%
Weight Reduction
20%
Bariatric Procedures
20%
Dual Agonist
20%
Biased Agonism
20%
People with Obesity
20%
Duodenum
20%
Paracrine Signaling
20%
Preclinical Experiment
20%
Tirzepatide
20%
Nutrient Delivery
20%
Endocrine Signaling
20%
Functional Antagonism
20%
Signal Controlling
20%
Duodenal mucosa
20%
Medicine and Dentistry
Gastric Inhibitory Polypeptide
100%
Maturity Onset Diabetes of the Young
100%
Enteroendocrine Cell
100%
Receptor
33%
Secretion (Process)
33%
Incretin
33%
Glucagon Like Peptide 1
33%
Internalization
33%
Body Weight Loss
16%
Body Weight
16%
Clinical Study
16%
Glucagon Like Peptide 1 Receptor
16%
Hyperglycemia
16%
Blood Glucose
16%
Glycemic Control
16%
Bariatric Surgery
16%
Tirzepatide
16%
Duodenum Mucosa
16%
Duodenum
16%
Pharmacology, Toxicology and Pharmaceutical Science
Gastric Inhibitory Polypeptide
100%
Non Insulin Dependent Diabetes Mellitus
100%
Incretin
40%
Glucagon-Like Peptide-1
40%
Receptor
20%
Hyperglycemia
20%
Gastric Inhibitory Polypeptide Receptor
20%
Glucagon-Like Peptide 1 Receptor
20%
Clinical Study
20%
Tirzepatide
20%